Iressa
/
Iressa is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations. It is administered as an oral tablet and is available by prescription only. Patients are advised that Iressa may cause liver problems and should not be used in individuals with severe liver impairment.
Mechanism of Action
Iressa, which contains the active ingredient gefitinib, works by blocking certain signals that help cancer cells grow and divide. Think of it as a key that fits into a lock, preventing the lock from turning and stopping the cancer cells from getting the signals they need to thrive.
The pharmacologic mechanism of gefitinib involves selective inhibition of the epidermal growth factor receptor (EGFR) tyrosine kinase. By binding to the ATP-binding site of the EGFR, gefitinib inhibits the receptor\
25
commonly-prescribed
medication.